Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another Zomedica Target VCA Animal Hospitals is a leading provider of pet health care services in the country delivered through over 800 small animal veterinary hospitals in the US and Canada. They follow each other on Twitter!
This deal saves VCA approximately $6,400,000 in equipment costs.
this deal will bring in more Vets this saves a lot of money for vets with practices like VetCor and a free Truforma while the program is available. After those 5 initial assays are out this deal is expired. Only a few months away.. I see us having a great Q4 earnings and even better Q1 due to placements and PulseVet revenue!
securing 460 devices for free while the 5 assays are still not out, saves VetCor $3,600,000 in equipment! They should be acting upon it, if their smart about cutting costs ,increasing profits, productivity and efficiency for themselves and their clients!
Who thinks Zomedica is targeting VetCor Family of 460 Offices Across the North East! Best part Zomedica does follow them on Twitter. Should say a lot about targeting their Practices!
Truforma is free for Every Veterinary Practice til 5 Assays are fully out!
VETS WILL TAKE ADVANTAGE.
VetCor has 460 locations free Truforma for each office why not that’s more then 3M in devices they will be securing for free!
Razor Blade System gonna be ??????
Update 2018 annual revenue was at 5 Million for PulseVet
After Diagnostic Pipeline is Complete
Focus will be on Therapeutic Pipeline
2021/2022 ZM-017 News
2022/2023 ZM-020 News
2020 No Product just a Pipeline
2021 Truforma & PulseVet
2020 Cash on Hand 50 Million
2021 Cash on Hand 200 Million
2020 6/7 Cents Bottom
2021 50 Cents Bottom
For Oct. 31, 2021 “Zomedica Corp. has chosen Larry Heaton as its next chief executive, the Ann Arbor, Mich.-based veterinary company said Monday. Mr. Heaton was appointed president of Zomedica on Friday. He is slated to take over the CEO role on Oct. 31 from Robert Cohen, who is retiring.”
https://www.marketwatch.com/story/zomedica-names-larry-heaton-next-ceo-271633342452
Any annual revenue Pulse Brings in goes in our earnings.. so say it’s 15M by 4 quarters is 3.75M low end.. high end 6.75m each quarter in revenue.. our expected revenue is at 1.5 million in Q1 we will make double expected revenue. https://money.cnn.com/quote/forecast/forecast.html?symb=ZOM
Also have doing research realized how much would pulse vet tech will bring in for Zomedica.. Annual revenue for pulse was 9m in 2019, 2020 was 20m, 2021 I would suspect perhaps supply shortage and not knowing what they brought in I would low end side 15M if they had no trouble I would say they are growing and perhaps 25/30M in annual revenue.
in Feb 26, 2021
“Liquid Biopsy” Platform
We have performed initial development work on a circulating tumor cell (CTC) “liquid biopsy” platform for use in a reference lab setting as a canine cancer diagnostic. This platform is intended for use to detect canine cancers faster, more affordably and less invasively compared to existing methods, which can be expensive and cost prohibitive for pet owners. We have worked on the development of an assay for use with this platform that targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma. This platform is being developed together with Celsee, Inc., a Bio-Rad Laboratories company, or Celsee.
In early 2020, we successfully completed the development and manufacturing milestones for our liquid biopsy platform.
Consistent with our focus on the development of point-of-care diagnostic platforms, we intend to seek one or more partners for the further development and commercialization of the liquid biopsy platform.
on Jan 20, 2020 ZM-017
In accordance with Zomedica’s focus on point-of-care diagnostic testing, Zomedica intends to seek partners to continue development and commercialization of the hemangiosarcoma, osteosarcoma, and lymphoma assays and the related instruments which are intended to be used in an offsite reference lab, as well it’s therapeutic assets Zomedica believes that there is no pre-market regulatory burden to commercializing in the United States.
on Jan 20, 2020 with the development work phase completed, Zomedica and Celsee have amended and restated the Celsee agreement to acknowledge the completion of the initial development work and to provide for definitive supply and pricing terms for the liquid biopsy instrument and related consumables.
I expect news about a diagnostic device commercialization ZM-017 in the pipeline the one with
$BIO
in 2022 before EOY
Sorry didn’t have my coffee this morning there’s another sec filing incoming for today. So let’s see
New CEO Exercising Stock Options 10,000,000
https://www.sec.gov/Archives/edgar/data/1213207/000117184321006834/xslF345X03/ownership.xml
Mr. Heaton has had seven U.S. patents issued to date with 15 additional patents pending, related to enhancements of products designed to facilitate their effective commercialization. He has served as a member of the board of several international medical societies and foundations, including the MITAC Board for the commercialization of NASA technology via partnerships with the medical industry.
In connection with newly appointment CEO, the Company’s Board of Directors granted to Mr. Heaton options to purchase an aggregate of 10,000,000 common shares at an exercise price of $0.58 per share under the Company’s Amended and Restated Stock Option Plan. The options will vest in four equal annual installments, beginning on the one-year anniversary of the date of grant and will expire on the tenth anniversary of the date of grant, subject to earlier termination upon the occurrence of certain circumstances.
Thanks bro .. Same to you bud!
Okay let’s see which markets last longer not that I’m not into crypto haha
Larry has 35 years of Experience as a CEO
Cohen is old .. he came in on September 2020 with a plan not to stay long interm ceo and became the ceo in December or January if I recall .. I knew he just had to play chess board and put things into motion. If he’s leaving he completed his job with Zomedica and going on board team to retire.
Those was assumptions obviously after the cash load we can afford to buy companies and get our company into position to probably sold LT after the two other devices come out in pipeline.. with everything at play here Zomedica can position themselves into market opportunities and have a valuation anywhere from 30-40 billion dollars after it releases its pipeline to broader market.. you can’t say the M/A of Pulse Vet isn’t clutch.. they will buy out more companies with 200m .. Robert Cohen is on the board team still his mind is with us.. we needed a fresh start.. Cohen did his job he got us 240m in capital he put Blair and Sean together and I see us buying more companies and I suspect before year ends.. he said they have options I see them shopping their options they don’t need that much capital.. positive cash flow is expected by 2023 and I see it coming sooner with more positive cash flow buy outs like pulse vet.
oh yea Q4,Q1 will be even better, i see earning beating earnings with their razer blade sales system!
Chase the Rips, or Buy the Dips
Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan
October 04 2021 - 06:05AM
Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that Larry Heaton has been appointed President effective October 1, 2021. Mr. Heaton will assume the role of Chief Executive Officer upon the retirement of current Chief Executive Officer Robert Cohen on October 31, 2021. Following his retirement, Mr. Cohen will remain on the Board of Directors of Zomedica.
Mr. Heaton brings to Zomedica more than 35 years of executive leadership and operations experience from the medical device and biotechnology industries with an extensive focus on commercialization and business development in both large cap and early-stage medical device companies. Mr. Heaton was awarded a Bachelor of Arts degree from Eastern Illinois University, and is an inventor on several U.S. patents. He has served as a member of the board of several international medical societies and foundations, including the MITAC Board for the commercialization of NASA technology via partnerships with the medical industry.
Most recently, Mr. Heaton was President, Chief Executive Officer and Director of Flowonix, Inc., a privately held company marketing implantable drug-delivery systems for the management of pain and spasticity. Prior to that, Mr. Heaton was President, Chief Executive Officer and Director of Cardiox Corporation, a privately held company that developed and marketed drug-device combination products for the structural heart and liver diagnostics markets. Previously, he served as President, Chief Executive Officer and Chairman of the board of Vioptix Inc., a privately held company in the tissue oximetry field, President, Chief Executive Officer and Director of Curon Medical, Inc., a public company marketing products for the treatment of gastrointestinal disorders, and President, Chief Executive Officer and Director of Response Genetics, Inc., an applied genomics start-up firm providing gene expression services in the oncology market.
Mr. Heaton's earlier career spanned 18 years at United States Surgical Corporation (USSC), a leading manufacturer of innovative wound closure and advanced surgical products, serving in roles of increasing responsibility in Sales, Marketing and General Management. His career at USSC culminated in his serving as President and Chief Operating Officer of USSC from 1998 through 2000.
The Board of Directors recruited Mr. Heaton in part due to his successful track record in building early-stage companies and developing and launching therapeutic and diagnostic medical devices and biotechnology products.
Mr. Robert Cohen, Chief Executive Officer, commented: “I and the entire Board of Directors are very pleased to welcome Larry to Zomedica. When I announced my impending retirement last July, we began a nationwide search for my successor. We are excited to have attracted a candidate of Larry’s high caliber. His extensive experience, especially in commercial matters, is an excellent fit for Zomedica during this phase of its development. I look forward to working with Larry over the next month and then to continue supporting his efforts from my position on the Board of Directors. I am confident that Zomedica will be in very competent hands.”
“I am excited to join the team at Zomedica at this juncture,” commented Larry Heaton, “as I believe that Zomedica has an abundance of opportunity to grow both organically and through business development. The TRUFORMA® point-of-care diagnostic platform represents a significant advancement in the technology available to companion animal Veterinarians. With its potential capability to deliver reference-lab quality diagnostic information to the Veterinarian at the point of care, I believe that it will enable them to improve the quality of care for the companion animals they treat, enhance customer satisfaction for pet owners and increase profitability for their practices. My goal is for the TRUFORMA® point-of-care diagnostic platform to become an indispensable part of the Veterinarian’s practice by expanding the array of tests available.”
Mr. Heaton continued, “Additionally, the PulseVet acquisition announced last week reflects the opportunity to utilize available capital to expand our offerings to our combined customer base. Our goal is to continue to add high quality value-added products for companion animal veterinarians to leverage our combined sales and marketing organizations. I look forward to working with the talented and dedicated teams at Zomedica and PulseVet to make these goals a reality."
Opened the Doors for Global Commercialization! Thanks to PulseVet
Easy Money for more $ZOM shares $BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are still all over this.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM ?? it acquired Pulse Vet
$BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are all over this now.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM 💎 pic.twitter.com/wJVS4lZydq
— BL3 (@SellingStrikes) October 3, 2021
"Gauging momentum and affirmation of trend"
(Awesome Oscillator)(AO)
10/09/20 (Red vertical line) AO shows red candles faced down and deepest negative resistance before mainly positive momentum (green candles) following thereafter.
11/13/20 (Orange vertical line) MACD crossed above and turned green. TSI (True Strength Index) crossed above as well.
12/18/20 (Green vertical line) AO shows the green bar above and continually increasing there after. This confirms strengthening of positive momentum.
09/10/21 (Second Red vertical line) (REPEAT) shows red candles faced down and deepest negative resistance before gaining positive momentum (green candles) following there after.
Next up;
Second Orange vertical line like the first orange line (MACD/TSI will cross above)
Second Green vertical line like last green line (AO) green bars will cross above and continually increase, confirming positive momentum is strengthening.
With placement in Japan and Russia last week we are moving up soon
Wrong Board ??
Your treating this as a trade this is an investment play for LT growth .. if your trading this get in low get out high easy money rinse and repeat.. it has its days but I know catalyst coming up I know the stock well.. the whole market went sideways heavy manipulation and shorting .. but it’s in a full reversal.. I’m not worried about their investor relations not answer imagine how many people would be non stop crying to them.. why not go visit the headquarters like another Zom long holder, but regardless I’m hold 500,000k+ shares and contacted the IR once got that data I needed in august 2020 and started building my position.. Price Target is $5+, when it comes it comes but don’t think it’s gonna stay in one place while your trading gotta be doing both my friend that’s what I been doing and it’s working really well for me. Zomedica is an easy Valuation of 40 Billion in my eyes in the next 10 years with 200m on hand. They will blow up! 300k followers on Webull.. Stocktwits 130k followers.. most shorted stock in NYSE, it’s been called a meme stock when it wasn’t even close to meme stock WSB nor anyone cared for $ZOM.. remember pipeline news was for 2021 on two new devices.. assay news this month.. q4 earning in November and December new ceo news.. sounds like a lot of expected catalysts are incoming in a season for small and mid cap stocks
The jizzz is we bought a company all in cash.. that brings in 5 million annually comes out to 1.25m each quarter .. company deals mostly with horse and they are already global leader in their field .. 1,500 Truforma customer going forward is an easy bet.. they use a razer blade system for sales like we do. Also hearing we closing a deal with a Vet Corp with 400+ offices.. we caught traction and an uptrend is clearly visible building support till we surpass $1 then we build support there
Best part of the deal their buying 70million in shares for the company, all cash stock deal, means they took the deal knowing Zomedica will grow and they will have more then 70million in future growth with Zomedica.
The deal does this by putting PulseVet’s “trode” technology under the Zomedica umbrella. The X-Trode, PulseVet’s newest product, is showing great promise as a method of shock wave therapy for both indoor pets and farm animals. Additionally, the trodes are disposable and ready to use without sedation. According to the press release, the company has already employed the devices across 1,500 veterinary clinics worldwide.
This transaction will do great to beef up Zomedica’s roster of technology ready to deploy to customers around the globe.